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Abstract 
Patients with highly active Multiple Sclerosis 
can be started on the newer pharmaceutical agents, 
Dimethyl Fumarate or Fingolimod. Safety 
monitoring recommended includes regular blood 
analysis and also ophthalmic tests and MRI scans in 
the case of Fingolimod.  
The aim of this audit is to verify whether timely 
investigations are being taken, checked and results 
documented in a database and whether the 
appropriate action is being taken should safety 
become a concern.  
Method: An Excel document shared by all 
four Neurology consultants documents the patients’ 
personal details, any baseline investigations or other 
recommended tests taken and the blood results 
taken at regular intervals. This data was analysed 
for accuracy by keeping it up to date. The products’ 
SPC recommendations were used as guidelines and 
the time-frame modified locally. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results: After analyzing all the blood tests 
taken while on Dimethyl fumarate, 39% of patients 
took their regular blood tests on time; 31% were not 
taken on time and 30% had no blood tests taken at 
all. On the other hand, only 59% of patients on 
Fingolimod took their blood tests on time. 82% of 
the blood results were documented in their Excel 
document. A repeat MRI scan 6 months after 
starting Fingolimod showed that only 53% took it 
on time. 
Conclusion: Using an Excel document was a 
trial to try and ensure compliance with these 
recommendations. However, this audit clearly 
documents that it is not enough to follow patients 
on a regular basis, highlighting the need for a 
specialist nurse to monitor such patients.   
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Introduction  
Multiple Sclerosis (MS) is a chronic, 
autoimmune, inflammatory, demyelinating 
neurological condition of the central nervous 
system (CNS) whereby the T-cell mediated immune 
system destroys the myelin and axons in varying 
degrees. MS is a progressive disorder that has an 
unpredictable and varied course. Initially, the 
symptoms are reversible as demyelination heals 
incompletely; however, prolonged demyelination 
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causes axonal loss and clinically progressive 
symptoms. The trigger is unknown, although it is 
thought to have a combination of genetic 
predisposition and environmental factors, such as a 
viral infection early on in life.
1
 
The mean age of onset is usually between 20 
to 40 years 
2
 and women are twice more likely to be 
affected than men.
3
 It has a higher prevalence in 
Caucasians and in temperate countries such as 
Northern European countries, possibly linked to 
low levels of circulating Vitamin D.
1
 
There are four major categories of MS based on the 
course of the disease:
4
 
1. Relapsing-remitting MS (85% of patients): 
The most common form, it is characterised by 
flare-ups (relapses or exacerbations) of 
symptoms followed by periods of remission. 
2. Secondary progressive MS: may develop in 
patients with RRMS as the disease progresses. 
Periods of remission lessen and symptoms 
may not disappear completely as disability 
accumulates. 
3. Primary progressive MS (10% of patients): 
There is a steady decline as symptoms 
continue to worsen from the start of the 
disease with no relapses/remissions, although 
there may be occasional plateaus. This is the 
most challenging type to manage as it is 
resistant to most drugs used in MS. 
4. Progressive-relapsing MS (5% of patients): 
This rare form of MS is progressive from the 
start with intermittent flare-ups along the 
course and no periods of remission.  
MS has a wide range of symptoms and signs 
on presentation but it usually presents 
monosymptomatically.
1
 Patients can present with 
visual symptoms such as diplopia, unilateral optic 
neuritis; sensory disturbances including dysthaesia 
(burning and “pins and needles”) or paraesthesia 
(numbness or tingling); motor symptoms such as 
leg weakness; or also brainstem or cerebellar 
symptoms including ataxia, vertigo, tremor etc. 
Early on, relapses may be followed by 
remission and full recovery. Since it is a 
progressive disorder, with time remissions 
becoming shorter and less frequent and may not 
return back to normal in between flare-ups as 
disability accumulates.  
At Mater Dei Hospital, the new Disease-
Modifying Agents (DMA’s) used in highly active 
relapsing-remitting multiple sclerosis include 
Dimethyl fumarate and Fingolimod. According to 
the Summary of Product Characteristics (SPC) of 
Dimethyl fumarate, one of the precautions 
mentioned include close monitoring of the patients’ 
blood tests at regular intervals to look out for 
lymphopenia, changes to the hepatic and renal 
function, and MRI imaging if at increased risk of 
Progressive Multifocal Leukoencephalopathy 
(PML). The SPC of Fingolimod also recommends 
regular blood tests to look out for lymphopenia and 
hepatic impairment. In addition, all patients should 
have an ECG and blood pressure measurement 
performed prior to and 6 hours after the first dose of 
Fingolimod in view of the risk of bradyarrythmia, 
MRI imaging to assess for the risk of PML, and an 
Ophthalmology review after 3 months of starting 
treatment to look out for macular oedema. In view 
of the serious consequences that may arise should 
any shortcomings occur, the Neurology consultants 
within Mater Dei Hospital started an Excel 
document to try and ensure compliance with these 
safety measurements.  
 
Methods 
Approval was sought from the Data Protection 
Office and University Research Ethics Committee, 
with endorsements from all four Neurology 
Consultants. An Excel document shared between 
the four consultants keeps track of all patients on 
Dimethyl fumarate and Fingolimod. It documents 
patients’ personal details, starting date of 
treatments, any baseline investigations or other 
recommended tests taken, and blood results taken at 
regular intervals. The products’ SPC 
recommendations are used as guidelines to identify 
what tests are needed to be taken regularly.  
The time-interval was set as bi- or tri-
monthly, as agreed between the consultants. The 
results were either documented as “on time” (i.e. 
taken within the 30-day period of that month), “not 
on time” (i.e. outside of the 30-day window), or 
“not taken” (no blood results taken 1 month before 
or after the anticipated month were found). All 
blood tests were taken at Mater Dei Hospital and 
the results were found on the computer programme 
iSoft Clinical Manager; thus excluding any tests 
performed in the private sector. Patients that 
stopped treatment or were lost to follow-up did not 
have any further blood tests taken regularly. 
According to Fingolimod’s SPC recommendations, 
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patients should have a repeat MRI after 6 months of 
starting medication to ensure there is no 
relapse/disease progression. 
The Excel document was accessed during the 
first week of January 2016 and any data inputted up 
to this date was analysed for accuracy, kept up-to-
date with the latest blood results, and any 
documented actions taken, without consulting each 
patient’s personal Medical file.  
 
Results 
Dimethyl fumarate 
 The bar graph in Figure 1 was created to show 
how many of the 38 registered patients on Dimethyl 
Fumarate had their blood tests actually taken on 
time, how many were not taken on time, how many 
were not taken at all and how many are still pending 
at timely intervals (x-axis). No clear pattern is 
observable, however one can note that over time 
there were less tests taken (on time and not on time) 
while there are increasing pending tests in view of 
new patients being started on Dimethyl fumarate. 
 Since one cannot assume or predict how the 
pending tests will behave, as either taken on time or 
not on time, our existing data needs to be 
interpreted without taking them into consideration. 
Therefore, after deducting the pending tests, the pie-
chart in Figure 2 shows that up to 39% of the tests 
taken so far were done in a timely fashion; whilst, 
31% of such tests were not taken on time according 
to the predetermined timeframe. Moreover, up to 
30% of the regular assessments were not taken at all 
since no results were shown on iSoft. Therefore, 
altogether up to 70% of tests were taken whilst one-
third have lost their opportunity to be adequately 
monitored for any abnormalities (Figure 2).   
 
Fingolimod 
From the blood tests actually taken, 68 out of 
115 total tests were taken on time, making up just 
59% of the total tests. On the other hand, a little less 
than half of the tests were not taken on time, as 47 
tests out of 115 tests, i.e. 41% of them, were taken 
at an earlier or later date than the predetermined 
timeframe (Table 1) (Figure 3).  
If one were to analyse whether blood tests 
results were chased, acknowledged and documented 
in their Excel database, one will find that the 
majority (i.e. 82%) were clearly documented whilst 
only 18% were found to be not documented in their 
database. The results were found in iSoft Clinical 
Manager, indicating that the patient had taken the 
test but it was unclear whether the result was chased 
by the firm (Table 2) (Figure 4).  
Out of 23 patients registered, only 19 had their 
6-monthly MRI taken, of which 10 were taken on 
time, 3 were taken at an earlier date whilst 6 had 
the MRI taken at a later date. The MRI date was 
late by 1 month at the lowest and 4 months by the 
highest. These would tally up to 53% of the MRI’s 
taken on time, 16% taken at an earlier date and 32% 
taken late (Table 3) (Figure 5).  
 
Figure 1: Blood tests taken at set intervals for Dimethyl Fumarate 
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 Figure 2: Percentage for total blood tests booked for Dimethyl Fumarate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Timely blood tests taken on Fingolimod treatment 
Timely Blood tests 
Blood tests taken on Time 68 59% 
Blood tests NOT taken on time 47 41% 
Total tests performed 115  
 
 
 
Figure 3: Timely blood tests taken for Fingolimod 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Blood test documentation in Excel database on Fingolimod 
 
Blood test result documentation in Excel database 
Result documented 94 82% 
Result not documented 21 18% 
Total results available 115  
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Figure 4: Result Documentation in Database for Fingolimod 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3: 6 months MRI surveillance while on Fingolimod 
6 Months MRI surveillance 
Total patients performed 19  
MRI taken on time 10 53% 
MRI taken at an earlier date 3 16% 
MRI taken at a later date 6 32% 
 
Figure 5: Percentage of 6-Months MRI scan while on Fingolimod 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
Dimethyl fumarate - (Tecfidera®) 
After collecting and interpreting all the data, a 
number of observations were noted. In a few cases, 
not all three blood tests (CBC, U&E, Cr and LFT’s) 
were taken as baseline before starting treatment, 
taken regularly every month or screened for any 
abnormalities from their baseline.  
While in their database it was stated that 
baseline bloods were available on a particular date, 
on three occasions these could not be traced on the 
iSoft programme, raising the question whether they 
were actually taken and the source of their claim. In 
other instances, the starting date of treatment was 
not stated in the Excel database. There were cases 
where the predicted timeframe for due tests did not 
correspond with the starting date of treatment as 
documented in their database. This made it 
debatable whether treatment was actually started on 
the date as stated, or whether the tests were 
routinely taken 1 month later. 
While searching for their regular blood tests 
on iSoft, it was noted that some of the values were 
not documented on their Excel database, raising 
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concerns whether they were chased and 
acknowledged. Moreover, some lymphocyte results 
were not documented in the right tab on their Excel 
database – For example, the 2nd and 4th month 
results were swapped. 
On three occasions, the lymphocyte count was 
noted to drop below 0.5 x10
9
/L. Despite this, no 
action was documented in their Excel sheet as to 
whether this treatment was temporarily suspended 
to allow the lymphocyte count to recover, as 
advised by the product’s SPC recommendations. 
Some patients had pending blood tests 
showing on iSoft Manager for the upcoming 
months, while for the majority they had no 
upcoming blood tests ordered. This raised concerns 
on how compliance was monitored and whether 
checks were made to ensure patients had an 
appointment set for blood-letting. 
 
Fingolimod - (Gilenya®) 
Similarly to Dimethyl fumarate, not all three 
blood tests (CBC, U&E, Cr and LFT’s) were taken 
as baseline before starting treatment, taken regularly 
every month or screened for any abnormalities from 
their baseline. 10 patients out of the total of 23 did 
not have documentation of their 3-month 
ophthalmological examination, whether it was 
performed or the exam’s conclusion in the Excel 
document. 
Some MRI tests did not have their results 
documented in their Excel database, making it 
uncertain whether they were chased and 
acknowledged in a timely fashion. 16% of the 6-
monthly MRI were taken earlier, possibly 
performing it during a suspected relapse when the 
patient exhibited signs and/or symptoms.   
Not all patients had blood tests booked on 
iSoft programme for the upcoming months. This 
made it difficult to ensure compliance from the 
patient to take their blood tests on time. On 7 
occasions in total, the blood test results documented 
on their Excel database did not match the true 
results as taken from the iSoft computer 
programme. In one case, two sets of results were 
swapped as the 6
th
 and 9
th
 month result respectively.  
While searching for patients’ regular blood tests on 
iSoft, it was noted that some of the values were not 
documented on their Excel database, thus raising 
concerns whether they were chased and 
acknowledged. 
In two cases, the lymphocyte count had 
dropped less than 0.2 x10
9
/L (0.16 and 0.17) with 
no documented action keyed into their database. On 
the other hand, two particular patients were 
documented as “monitoring lymphocyte count and 
to decide on further management”. One of these had 
discontinued Fingolimod indefinitely in view of 
recurrent lymphopenia. 
After 12 months, according to the consultants’ 
database it states any further blood tests to be taken 
as “regular follow-up”. However, there was no clear 
pattern as to how often this should have been taken. 
In fact, some tests were sparsely taken and in other 
occasions were taken too close to each other to 
observe for any abnormalities. Only one consultant 
kept a regular time-frame after the 12
th
 month, 
which made it easier to keep track of the patient’s 
blood tests and MRIs due.  
 
Conclusion 
The use of Dimethyl fumarate and Fingolimod 
require a number of investigations to be taken 
before starting treatment to ensure that the right 
candidate is eligible for these DMA’s. In addition, 
close follow-up of these patients with regular blood 
tests, MRI scans and an ophthalmological review 
are necessary to ensure no complications arise. The 
SPC recommendations are clearly documented and 
any shortcomings can have serious consequences.  
In view of this, the consultants within the 
Neurology Department felt the need to utilise an 
Excel document as a trial to try and ensure 
compliance with these recommendations. However, 
this audit clearly documents that it is not an easy 
task as it is quite time-consuming and laborious. As 
a result, the Excel document was not used 
appropriately, and clearly it is not enough to follow 
patients on a regular basis.   
Therefore, the suggestions below may help to 
alleviate the problem and ensure better compliance 
in the future; 
1) A qualified specialist nurse would be highly 
beneficial to educate, support and advise 
patients to take regular blood tests and stress 
the importance of compliance. He/she would 
work with the professional backup offered by 
Neurologists should a problem arise. 
2) Ensure each patient has a set of baseline blood 
tests, including all three tests (CBC, U&E, 
LFT’s), taken before initiating therapy. 
3) All three blood tests should be regularly 
booked and screened for any abnormalities 
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during their appointment, namely the 
lymphocyte count and the liver hepatic 
enzymes. 
4) Patient should be provided with set 
appointments according to the timeframe set 
in the Excel database and if they do not show 
up by mid-month, they can be reached via 
phone/email/SMS and reminded of their 
appointment. 
5) Once the test has been taken, the result should 
be chased and acknowledged by the nurse and 
inputted in the Excel database in the correct 
order. 
6) Should there be any concerns, the nurse can 
discuss the issues with the Neurologist for any 
action required. These should then be clearly 
documented in the Excel database for future 
reference. 
7) The specialist nurse would also act as the 
point of contact should the patient report any 
symptoms or signs of an infection to check 
their latest lymphocyte count, concerns about 
the treatment’s side-effects, queries about 
appointments and any other information 
required about their condition.  
8) Patients on Fingolimod, should have regular 
Liver Function Tests taken and assessed for 
any abnormalities. Results should be 
documented in case there are elevated liver 
enzymes which if >5 times UNL, would 
necessitate suspending treatment temporarily 
as advised by the SPC recommendations.  
9) In view of a high rate of patients suffering 
from Diabetes Mellitus locally, such patients 
taking Fingolimod would benefit from regular 
ophthalmological examinations and not just as 
baseline and at 3-months of therapy. Macular 
oedema may develop with or without visual 
disturbances.  
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